← Health care and life sciences companies

    Adimab: company profile, size and contacts

    adimab.comActiveFor profit

    Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.

    Employees
    101-250
    Founded
    2007
    Total raised
    $45.5M
    Monthly visits
    1,971

    Company facts

    Website
    adimab.com
    Location
    East Coast, New England, Northeastern US
    Employees
    101-250
    Founded
    2007 (19 years ago)
    Categories
    Biotechnology, Collaboration, Health Care, Therapeutics
    Company type
    For profit
    Listing
    Private
    Industry code (NAICS)
    6211 Offices of physicians; 3254 Pharmaceutical and medicine manufacturing
    Industry code (SIC)
    8000 Health services; 2834 Pharmaceutical preparations

    Founders

    • Errik AndersonFounder · Adimab
    • K. Dane WittrupFounder · Adimab
    • Tillman GerngrossFounder · Adimab

    Adimab was founded in 2007 by Errik Anderson, K. Dane Wittrup, Tillman Gerngross.

    Funding

    Total raised
    $45.5M
    Funding rounds
    8
    Latest round
    Series unknown, 2020-01
    Investors
    6
    Lead investors
    3
    Exits
    1
    Investments made
    2

    Adimab's investment strategy appears to focus on early to mid-stage companies within the biotechnology, pharmaceutical, and therapeutics sectors, specifically those that align with health care, science, and engineering industries. The firm's investments are geographically concentrated in the United States, with a preference for entities located in Massachusetts. Adimab does not typically take a lead role in the funding rounds it participates in. The company's approach suggests a strategic interest in innovative firms that are likely to contribute to the expansion of biologics pipelines and complement Adimab's antibody discovery and optimization platform. Organizations that could attract Adimab's attention for future investments are likely to be U.S.-based biotech firms with a focus on novel therapeutic development, potentially those working on antibody technologies or other areas that can synergize with Adimab's platform and expertise.

    Web and app presence

    Monthly website visits
    1,971
    Global traffic rank
    #4,702,625

    How Adimab compares

    • Size: Adimab has more employees than 69% of the 1251 health care and life sciences companies in our directory that report it.
    • Age: Adimab is older than 46% of the 1166 health care and life sciences companies in our directory that report it.
    • Web traffic: Adimab gets more monthly website visits than 50% of the 1233 health care and life sciences companies in our directory that report it.

    1282 health care and life sciences companies are in the directory, 165 of them in the same 101-250 employee range and 75 based in East Coast.

    Growth outlook

    • Trend: Growing
    • Direction: Growing
    • Confidence: Medium

    Adimab may be growing as indicated by the recent announcement of a substantial expansion of its research campus. This expansion suggests an increase in operational capacity and potentially a broadening of its research and development activities. Such a move typically reflects a positive trajectory in a company's growth, as it often requires significant investment and implies confidence in future business prospects. The expansion of a research campus in the biotechnology industry, where Adimab operates, is a strong indicator of growth, as it enables the company to enhance its capabilities in antibody discovery and optimization.

    What Adimab says about itself

    “Accelerate antibody therapeutics with Adimab’s yeast-based antibody discovery and engineering platform built for developability and clinical success.” adimab.com

    Adimab in short

    Adimab is a biotechnology company based in East Coast, with 101-250 employees, founded in 2007. Its founders are Errik Anderson, K. Dane Wittrup and Tillman Gerngross and it has raised $45.5 million over 8 rounds.

    Frequently asked questions

    What does Adimab do?
    Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
    When was Adimab founded?
    Adimab was founded in 2007, so it is about 19 years old.
    How many employees does Adimab have?
    Crunchbase lists Adimab in the 101-250 employee range.
    Where is Adimab based?
    Adimab is listed under East Coast, New England, Northeastern US.
    Has Adimab raised funding?
    Crunchbase records $45.5M raised across 8 funding rounds, most recently series unknown in 2020-01.
    How do I find email addresses at Adimab?
    Search the domain adimab.com with the Inbound Labs Domain Search or Email Finder to see verified contacts and departments. Individual addresses are shown after you sign up.

    Similar companies

    More in Health care and life sciences companies.

    Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.